Epidemiology, Pathogenesis and Management of Hepatitis D: Update and Challenges Ahead

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2010 Jan 7

PMID 20051970

Citations 121

Authors

Heiner Wedemeyer

Michael P Manns

Affiliations

Soon will be listed here.

Abstract

Hepatitis D is caused by infection with the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans. Hepatitis D occurs only in individuals positive for the HBV surface antigen (HBsAg) as HDV is a defective RNA viroid that requires HBsAg for transmission. At least eight different HDV genotypes have been described and each has a characteristic geographic distribution and a distinct clinical course. HDV and HBV coinfection can be associated with complex and dynamic viral dominance patterns. Chronic HDV infection leads to more severe liver disease than HBV monoinfection and is associated with accelerated fibrosis progression, earlier hepatic decompensation and an increased risk for the development of hepatocellular carcinoma. So far, only IFN-alpha treatment has proven antiviral activity against HDV in humans and has been linked to improved long-term outcomes. Studies conducted in the past 2 years on the use of PEG-IFN-alpha show that a sustained virologic response to therapy, measured in terms of undetectable serum HDV RNA levels, can be achieved in about one quarter of patients with hepatitis D. Novel alternative treatment options including prenylation inhibitors are awaiting clinical development for use in hepatitis D.

Citing Articles

Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation Results From a French Multicentric Retrospective Study.

Meszaros M, Hilleret M, Dumortier J, DAlteroche L, Abergel A, Latournerie M Liver Int. 2025; 45(3):e70033.

PMID: 39960163 PMC: 11831879. DOI: 10.1111/liv.70033.

Prevalence and molecular characterization of hepatitis delta virus infection among hepatitis B virus surface antigen positive students and pregnant women in N'djamena, Chad.

Debsikreo N, Dehainsala M, Debsikreo O, Leye N, Lo G, Dia A IJID Reg. 2025; 14:100560.

PMID: 39895833 PMC: 11786080. DOI: 10.1016/j.ijregi.2024.100560.

Furquim dAlmeida A, Ho E, Govaerts L, Michielsen P, Serste T, Bourgeois S J Viral Hepat. 2025; 32(2):1-15.

PMID: 39846497 PMC: 11756033. DOI: 10.1111/jvh.14060.

Dynamics of Virological and Clinical Response Parameters of Bulevirtide Treatment for Hepatitis D: Real-World Data.

Killer A, Gliga S, Lohr C, Weigel C, Jensen B, Lubke N Gastro Hep Adv. 2024; 3(3):353-360.

PMID: 39131142 PMC: 11308454. DOI: 10.1016/j.gastha.2024.01.001.

Prevalence of Hepatitis D in People Living with HIV: A National Cross-Sectional Pilot Study.

Schinas G, Antonopoulou N, Vamvakopoulou S, Tsachouridou O, Protopapas K, Petrakis V Viruses. 2024; 16(7).

PMID: 39066206 PMC: 11281684. DOI: 10.3390/v16071044.

References

Rizzetto M . Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterol Belg. 2000; 63(2):221-4. View

Taylor J . Hepatitis delta virus. Virology. 2005; 344(1):71-6. DOI: 10.1016/j.virol.2005.09.033. View

Zachou K, Yurdaydin C, Drebber U, Dalekos G, Erhardt A, Cakaloglu Y . Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 2009; 30(3):430-7. DOI: 10.1111/j.1478-3231.2009.02140.x. View

Dienes H, Purcell R, Popper H, Ponzetto A . The significance of infections with two types of viral hepatitis demonstrated by histologic features in chimpanzees. J Hepatol. 1990; 10(1):77-84. DOI: 10.1016/0168-8278(90)90076-4. View

Su C, Huang Y, Huo T, Shih H, Sheen I, Chen S . Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006; 130(6):1625-35. DOI: 10.1053/j.gastro.2006.01.035. View

Niro G, Ciancio A, Tillman H, Lagget M, Olivero A, Perri F . Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005; 22(3):227-32. DOI: 10.1111/j.1365-2036.2005.02542.x. View

Hershow R, Chomel B, Graham D, Schyve P, Mandel E, Kane M . Hepatitis D virus infection in Illinois state facilities for the developmentally disabled. Epidemiology and clinical manifestations. Ann Intern Med. 1989; 110(10):779-85. DOI: 10.7326/0003-4819-110-10-779. View

Niro G, Rosina F, Rizzetto M . Treatment of hepatitis D. J Viral Hepat. 2005; 12(1):2-9. DOI: 10.1111/j.1365-2893.2005.00601.x. View

Castellares C, Barreiro P, Martin-Carbonero L, Labarga P, Vispo M, Casado R . Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat. 2008; 15(3):165-72. DOI: 10.1111/j.1365-2893.2007.00903.x. View

10.

Raimondo G, Brunetto M, Pontisso P, Smedile A, Maina A, Saitta C . Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2005; 43(1):100-7. DOI: 10.1002/hep.20944. View

11.

Yurdaydin C, Bozkaya H, Onder F, Senturk H, Karaaslan H, Akdogan M . Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008; 15(4):314-21. DOI: 10.1111/j.1365-2893.2007.00936.x. View

12.

Rosenau J, Kreutz T, Kujawa M, Bahr M, Rifai K, Hooman N . HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol. 2007; 46(4):635-44. DOI: 10.1016/j.jhep.2006.11.022. View

13.

Dimitrakakis M, Gust I . HDV infection in the Western Pacific region. Prog Clin Biol Res. 1991; 364:89-96. View

14.

Niro G, Casey J, Gravinese E, Garrubba M, Conoscitore P, Sagnelli E . Intrafamilial transmission of hepatitis delta virus: molecular evidence. J Hepatol. 1999; 30(4):564-9. DOI: 10.1016/s0168-8278(99)80185-8. View

15.

Cross T, Rizzi P, Horner M, Jolly A, Hussain M, Smith H . The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2007; 80(2):277-82. DOI: 10.1002/jmv.21078. View

16.

Lau D, Doo E, Park Y, Kleiner D, Schmid P, Kuhns M . Lamivudine for chronic delta hepatitis. Hepatology. 1999; 30(2):546-9. DOI: 10.1002/hep.510300217. View

17.

Rizzetto M, Hoyer B, Canese M, Shih J, Purcell R, Gerin J . delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A. 1980; 77(10):6124-8. PMC: 350226. DOI: 10.1073/pnas.77.10.6124. View

18.

Castelnau C, Le Gal F, Ripault M, Gordien E, Martinot-Peignoux M, Boyer N . Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006; 44(3):728-35. DOI: 10.1002/hep.21325. View

19.

Radjef N, Gordien E, Ivaniushina V, Gault E, Anais P, Drugan T . Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. 2004; 78(5):2537-44. PMC: 369207. DOI: 10.1128/jvi.78.5.2537-2544.2004. View

20.

Gunsar F, Salih Akarca U, Ersoz G, Kobak A, Karasu Z, Yuce G . Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005; 10(6):721-6. View